Why is Biofil Chemicals falling/rising?

As of 23-Jun, Biofil Chemicals & Pharmaceuticals Ltd is currently priced at 46.50, showing no change (0.00%) from the previous trading session. The stock has been trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a downward trend. Additionally, there has been a significant decrease in investor participation, with delivery volume falling by 78.71% against the 5-day average. Over the past year, the stock has generated a return of -30.57%, and its operating profits have declined by 20.95% CAGR over the last five years, reflecting weak long-term fundamental strength. The company's return on equity is low at 4.50%, and it has a poor EBIT to interest ratio of 0.74, which further suggests challenges in servicing its debt.
In the broader market context, the stock's performance over the past week has been -6.74%, while the Sensex has seen a slight increase of 0.12%. This underperformance relative to the benchmark indicates that Biofil Chemicals is struggling more than the overall market. The company's flat results in net sales, which have decreased by 33.62%, along with its expensive valuation compared to peers, contribute to a negative outlook. Overall, the combination of weak financial fundamentals, declining investor interest, and poor performance relative to the market suggests that Biofil Chemicals is facing significant challenges that are likely contributing to its current price stagnation.